Literature DB >> 17018129

Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.

Hayden Lowenstein1, Akeesha Shah, Alan Chant, Abrar Khan.   

Abstract

It is assumed that complement and noncomplement-mediated mechanisms are similarly responsible for Campath-1H-mediated killing of all T-cell subtypes in vivo. However, the differing surface expression of CD52 on T-cell subtypes suggests that may not be the case. The purpose of this study is to determine the extent and mechanism of Campath-1H-mediated elimination of different T-cell subtypes in peripheral blood. Whole blood or lymphocytes isolated from peripheral blood of healthy volunteers by Ficoll density centrifugation were incubated with Campath-1H, with or without complement and/or serum, and the resultant T-cell elimination mechanisms studied. For CD4(+) T lymphocytes, 60% and 40% cell death and for CD8(+) T lymphocytes 23% and 77% cell death, in peripheral blood, was mediated by complement and noncomplement mediated mechanisms, respectively. CD4(+) T cells demonstrated approximately twice the amount of surface CD52 compared with CD8(+) T cells, consistent with primarily complement-mediated killing for CD4(+) T cells. Thus, peripheral blood supports differential and partial elimination of T-cell subtypes, suggesting that the complete T-cell elimination seen in transplant recipients is most likely due to contribution from other lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018129     DOI: 10.1111/j.1432-2277.2006.00382.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  17 in total

1.  Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.

Authors:  M R L Marco; E M Dons; D J van der Windt; J K Bhama; L T Lu; A F Zahorchak; F G Lakkis; D K C Cooper; M B Ezzelarab; A W Thomson
Journal:  Transpl Immunol       Date:  2013-10-09       Impact factor: 1.708

Review 2.  Homeostatic expansion as a barrier to lymphocyte depletion strategies.

Authors:  Nicholas A Zwang; Laurence A Turka
Journal:  Curr Opin Organ Transplant       Date:  2014-08       Impact factor: 2.640

Review 3.  The immunological function of CD52 and its targeting in organ transplantation.

Authors:  Yang Zhao; Huiting Su; Xiaofei Shen; Junfeng Du; Xiaodong Zhang; Yong Zhao
Journal:  Inflamm Res       Date:  2017-03-10       Impact factor: 4.575

Review 4.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 5.  Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Authors:  Akiko Furukawa; Steven A Wisel; Qizhi Tang
Journal:  Transplantation       Date:  2016-11       Impact factor: 4.939

Review 6.  Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia.

Authors:  Constantin A Dasanu; Doru T Alexandrescu
Journal:  MedGenMed       Date:  2007-11-15

Review 7.  Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.

Authors:  Jan Lycke
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

8.  Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.

Authors:  E M Dons; G Raimondi; H Zhang; A F Zahorchak; J K Bhama; L Lu; M Ezzelarab; J N M Ijzermans; D K C Cooper; A W Thomson
Journal:  Am J Transplant       Date:  2013-05-01       Impact factor: 8.086

9.  Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

Authors:  Yanping Hu; Michael J Turner; Jacqueline Shields; Matthew S Gale; Elizabeth Hutto; Bruce L Roberts; William M Siders; Johanne M Kaplan
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

Review 10.  Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era.

Authors:  Kaja Kasarello; Dagmara Mirowska-Guzel
Journal:  Immunotargets Ther       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.